Literature DB >> 4211020

Properdin factor D. II. Activation to D by properdin.

D T Fearon, K F Austen, S Ruddy.   

Abstract

The protein in the properdin pathway responsible for conversion of precursor factor D to D has been isolated and found to be identical with properdin. Sequential ion exchange and gel filtration chromatography demonstrated identity between properdin protein, measured by radial immunodiffusion, and the capacity to activate D to D, assessed by formation of the intermediate, EAC43B(D). Properdin, purified in this manner, was homogeneous on acid polyacrylamide disc gel electrophoretic analysis, with the band of protein corresponding to the position of eluates in the replicate gel capable of activating highly purified D. Demonstration of the homogeneity of purified D by alkaline disc gel electrophoresis, coupled with the linear stoichiometric hemolytic titrations of each factor, indicates that direct interaction between properdin and D generates D. Thus, activation of D by properdin represents a mechanism in the properdin pathway by which D becomes available for formation of the C3b-dependent C3 convertase.

Mesh:

Substances:

Year:  1974        PMID: 4211020      PMCID: PMC2139584          DOI: 10.1084/jem.140.2.426

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  18 in total

1.  Properties of highly purified human properdin.

Authors:  J Ensky; C F Hinz; E W Todd; R J Wedgwood; J T Boyer; I H Lepow
Journal:  J Immunol       Date:  1968-01       Impact factor: 5.422

2.  Some physical-chemical properties of chicken gamma-globulins and their pepsin and papain digestion products.

Authors:  H S Tenenhouse; H F Deutsch
Journal:  Immunochemistry       Date:  1966-01

3.  A method for increasing the sensitivity of radial-immunodiffusion assay.

Authors:  E Alpert; M Monroe; P H Schur
Journal:  Lancet       Date:  1970-05-23       Impact factor: 79.321

4.  Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3).

Authors:  L G Hunsicker; S Ruddy; K F Austen
Journal:  J Immunol       Date:  1973-01       Impact factor: 5.422

5.  C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1969-03       Impact factor: 5.422

6.  Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation.

Authors:  L G Hunsicker; S Ruddy; C B Carpenter; P H Schur; J P Merrill; H J Müller-Eberhard; K F Austen
Journal:  N Engl J Med       Date:  1972-10-26       Impact factor: 91.245

7.  Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement.

Authors:  H J Müller-Eberhard; M J Polley; M A Calcott
Journal:  J Exp Med       Date:  1967-02-01       Impact factor: 14.307

8.  C3 proactivator convertase and its mode of action.

Authors:  H J Müller-Eberhard; O Götze
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

9.  The relationship of glycine-rich -glycoprotein to factor B in the properdin system and to the cobra factor-binding protein of huan serum.

Authors:  C A Alper; I Goodkofsky; I H Lepow
Journal:  J Exp Med       Date:  1973-02-01       Impact factor: 14.307

10.  The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator.

Authors:  A P Kaplan; K F Austen
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

View more
  23 in total

1.  Roles of adipocytes and fibroblasts in activation of the alternative pathway of complement in inflammatory arthritis in mice.

Authors:  William P Arend; Gaurav Mehta; Alexandra H Antonioli; Minoru Takahashi; Kazue Takahashi; Gregory L Stahl; V Michael Holers; Nirmal K Banda
Journal:  J Immunol       Date:  2013-05-06       Impact factor: 5.422

2.  Familial properdin deficiency associated with chronic discoid lupus erythematosus.

Authors:  E R Holme; J Veitch; A Johnston; G Hauptmann; B Uring-Lambert; M Seywright; V Docherty; W N Morley; K Whaley
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

3.  Resolution and analysis of 'native' and 'activated' properdin.

Authors:  T C Farries; J T Finch; P J Lachmann; R A Harrison
Journal:  Biochem J       Date:  1987-04-15       Impact factor: 3.857

Review 4.  The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?

Authors:  Richard A Harrison
Journal:  Semin Immunopathol       Date:  2017-11-22       Impact factor: 9.623

5.  Solubilization of an activity regulating C3b function from Raji cell membranes.

Authors:  P Carlson; S Ruddy; D H Conrad
Journal:  Immunology       Date:  1982-05       Impact factor: 7.397

6.  Binding of activated properdin to untreated erythrocytes: a new function of activated properdin.

Authors:  T Konno; H Hirai; N Tamura
Journal:  Immunology       Date:  1978-02       Impact factor: 7.397

7.  The role of Fcgamma receptor polymorphisms and C3 in the immune defence against Neisseria meningitidis in complement-deficient individuals.

Authors:  C A Fijen; R G Bredius; E J Kuijper; T A Out; M De Haas; A P De Wit; M R Daha; J G De Winkel
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

8.  Complement activation in chronic liver disease.

Authors:  L E Munoz; D De Villiers; D Markham; K Whaley; H C Thomas
Journal:  Clin Exp Immunol       Date:  1982-03       Impact factor: 4.330

9.  Inherited complement deficiency in children surviving fulminant meningococcal septic shock.

Authors:  H H Derkx; E J Kuijper; C A Fijen; M Jak; J Dankert; S J van Deventer
Journal:  Eur J Pediatr       Date:  1995-09       Impact factor: 3.183

10.  Cutaneous necrotizing venulitis: a sequential analysis of the morphological alterations occurring after mast cell degranulation in a patient with a unique syndrome.

Authors:  N A Soter; M C Mihm; H F Dvorak; K F Austen
Journal:  Clin Exp Immunol       Date:  1978-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.